NEW AND CONTINUING PROGRAMS

The programs listed in this section of the report were active within the ADDF’s portfolio as of September 30, 2023.

*Indicates ADDF support of different programs led by the same researcher

**BIOMARKERS**

Biomarkers are tools used to diagnose a disease and assess its progression and response to treatment. These researchers aim to develop more accurate biomarkers for clinical trials.

- **John Gerdes, PhD**
  RIO Pharmaceuticals, Inc.
  Clinical Phase 0
  $308,869.00

- **Miia Kivipelto, MD, PhD**
  FINGERS Brain Health Institute
  Clinical Phase 2
  $310,000.00

**CELLULAR SENESENCE**

Senescent cells develop mechanisms to avoid the natural death cycle that should come to all cells, instead surviving, accumulating in the brain, and releasing toxins. This damages nearby healthy cells and causes brain inflammation.

- **Miranda Orr, PhD**
  Wake Forest University Health Sciences
  Clinical Phase 2
  $3,439,379.00

- **Wake Forest University Health Sciences**
  Clinical Phase 2
  $150,000.00

**GENETICS & EPIGENETICS**

These therapies target genetic risk factors like APOE and epigenetics, which regulate how much genes are expressed.

- **Ronald Crystal, MD**
  Weill Medical College of Cornell University
  Clinical Phase 1
  $3,006,472.00

- **Hussein Yassine**
  University of Southern California
  Clinical Phase 2
  $1,750,483.00
INFLAMMATION
These scientists are investigating drugs that protect against inflammation in the brain caused by disease and injury, which can accelerate or trigger Alzheimer’s.

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Phase</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Joseph</td>
<td>The Scripps Research Institute</td>
<td>Clinical Phase 1</td>
<td>$3,000,000.00</td>
</tr>
<tr>
<td>Eric Siemers, MD</td>
<td>Vaccinex Inc.</td>
<td>Clinical Phase 1</td>
<td>$2,992,766.00</td>
</tr>
<tr>
<td>Jeffrey Stavenhagen, PhD</td>
<td>Therini Bio</td>
<td>Clinical Phase 1</td>
<td>$5,000,000.00</td>
</tr>
<tr>
<td>Tony Giordano, PhD</td>
<td>NeuroTherapia, Inc.</td>
<td>Clinical Phase 2</td>
<td>$3,000,000.00</td>
</tr>
<tr>
<td>Krista Lanctôt, PhD</td>
<td>Sunnybrook Research Institute</td>
<td>Clinical Phase 2</td>
<td>$1,396,867.00</td>
</tr>
<tr>
<td>Marwan Sabbagh, MD</td>
<td>Dignity Health St Joseph’s Hospital and Medical Center</td>
<td>Clinical Phase 2</td>
<td>$1,396,475.00</td>
</tr>
<tr>
<td>Ronald van der Geest, PhD</td>
<td>Treeway B.V.</td>
<td>Clinical Phase 2</td>
<td>$2,143,020.00</td>
</tr>
</tbody>
</table>

MISFOLDED PROTEINS
These scientists are pursuing approaches to prevent or clear the accumulation of misfolded proteins, which causes damage to brain cells.

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Phase</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dirk Beher, PhD</td>
<td>Asceneuron SA</td>
<td>Clinical Phase 1</td>
<td>$2,200,000.00</td>
</tr>
<tr>
<td>Philip Scheltens</td>
<td>Vrije Universiteit Amsterdam</td>
<td>Clinical Phase 1</td>
<td>$855,541.00</td>
</tr>
<tr>
<td>Edward Huey, MD</td>
<td>Trustees of Columbia University in the City of New York</td>
<td>Clinical Phase 1</td>
<td>$532,335.00</td>
</tr>
</tbody>
</table>

MITOCHONDRIA & METABOLIC FUNCTION
As we age, mitochondria, the energy centers of our cells, can become impaired. These researchers are developing drugs targeting this dysfunction.

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Phase</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Edison, MD, MRCP, PhD, FRCPID</td>
<td>Imperial College London</td>
<td>Clinical Phase 2</td>
<td>$340,540.00</td>
</tr>
<tr>
<td></td>
<td>Imperial College London*</td>
<td>Clinical Phase 2</td>
<td>$3,000,000.00</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Phase</td>
<td>Amount</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>-------------</td>
<td>------------</td>
</tr>
<tr>
<td>Miia Kivipelto, MD, PhD</td>
<td>FINGERS Brain Health Institute</td>
<td>Clinical</td>
<td>$150,000.00</td>
</tr>
<tr>
<td>Imperial College London*</td>
<td></td>
<td>Phase 2</td>
<td>$2,999,865.00</td>
</tr>
<tr>
<td>David Livingston</td>
<td>Metro International Biotech</td>
<td>Clinical</td>
<td>$3,000,000.00</td>
</tr>
<tr>
<td>John Rathmacher</td>
<td>MTI BioTech Inc.</td>
<td>Clinical</td>
<td>$1,450,000.00</td>
</tr>
<tr>
<td>Emiliano Santarnecchi</td>
<td>Harvard Medical School/BIDMC</td>
<td>Clinical</td>
<td>$1,959,841.00</td>
</tr>
<tr>
<td>Ronald van der Geest, PhD</td>
<td>Treeway B.V.</td>
<td>Clinical</td>
<td>$2,994,122.57</td>
</tr>
<tr>
<td>Miles Berger, MD, PhD</td>
<td>Duke University</td>
<td>Clinical</td>
<td>$1,631,197.00</td>
</tr>
<tr>
<td>Paul Edison, MD, MRCP, PhD, FRCPI</td>
<td>Imperial College London</td>
<td>Clinical</td>
<td>$2,000,000.00</td>
</tr>
<tr>
<td>Dean Ornish, MD</td>
<td>Preventive Medicine Research Institute</td>
<td>Clinical</td>
<td>$2,500,000.00</td>
</tr>
<tr>
<td>Bruno Vellas, MD</td>
<td>Toulouse Centre of Excellence in Neurodegeneration,University Hospital Toulouse</td>
<td>Clinical</td>
<td>$300,000.00</td>
</tr>
<tr>
<td>Tom Megerian, MD, PhD</td>
<td>Cognito Therapeutics</td>
<td>Clinical</td>
<td>$4,556,150.00</td>
</tr>
<tr>
<td>Ronald Crystal, MD, PhD</td>
<td>LEXEO Therapeutics, Inc.</td>
<td>Clinical</td>
<td>$1,997,865.20</td>
</tr>
</tbody>
</table>

**NEUROPROTECTION**

As Alzheimer’s progresses, neurons (or nerve cells) lose their connections and begin to die, causing the loss of memory and other cognitive functions. These scientists are exploring “neuroprotective” treatment strategies to shield neurons from damage and death.
**PROTEOSTASIS**

Proteostasis is the “quality control” system for our proteins—which carry out most functions in our cells—and is responsible for the proteins’ correct formation and for recycling them after they are no longer needed.

Anne-Marie Li-Kwai-Cheung  
Wave Life Sciences  
Clinical Phase 2  
$1,190,392.00

---

**SYNAPTIC ACTIVITY & NEUROTRANSMITTERS**

Neurotransmitters carry signals across synapses, which are connections between neurons. These processes are critical for memory and cognition.

Gabriel Vargas, MD, PhD  
Curasen Therapeutics Inc.  
Clinical Phase 1  
$5,814,712.38

Clive Ballard  
University of Exeter  
Clinical Phase 2  
$3,024,684.00

Jeffrey Cummings, MD  
University of Nevada Las Vegas  
Clinical Phase 2  
$150,000.00

Cleveland Clinic Lou Ruvo Center for Brain Health*  
Clinical Phase 2  
$1,000,000.00

---

Simon Ducharme  
McGill University  
Clinical Phase 2  
$1,399,077.51

Giacomo Koch, MD, PhD  
Santa Lucia Foundation  
Clinical Phase 2  
$602,800.00

Santa Lucia Foundation*  
Clinical Phase 3  
$3,515,458.00

$77,058,911.66  
**TOTAL SUPPORT FOR NEW AND CONTINUING PROGRAMS**